Physician profile
John V Gates
NPI 1992773550
$1,705.45
in general payments reported to CMS, 2019-2025
14 companies · $228 in 2025
The $228 reported for 2025 was more than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $184 · 2020: $44.72 · 2021: $37.75 · 2022: $742 · 2023: $156 · 2024: $312 · 2025: $228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $697.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $696.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Y-Mabs Therapeutics, INC. | $727.72 | 2022-2024 | Danyelza |
| Jazz Pharmaceuticals INC. | $217.21 | 2019-2024 | Rylaze |
| Sobi, INC | $169.98 | 2022-2025 | |
| Genzyme Corporation | $138.60 | 2023-2025 | |
| Kite Pharma, INC. | $118.09 | 2019 | |
| Novartis Pharmaceuticals Corporation | $87.07 | 2019-2023 | |
| Servier Pharmaceuticals LLC | $78.31 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $45.37 | 2023 | Ultomiris |
| Pfizer INC. | $26.23 | 2024 | |
| Pharming Healthcare, INC. | $24.30 | 2023 | Ruconest |
| Chiesi USA, INC. | $20.53 | 2025 | Ferriprox |
| Medtronic, INC. | $20.53 | 2023 | Azure Xt Dr Mri Surescan |
| Shorla Oncology INC. | $16.26 | 2025 | |
| Uswm, LLC | $15.25 | 2025 | Iwilfin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Gates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.